Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): Association with malignant transformation

被引:24
作者
Isaksson, E
Bjorkholm, M
Holm, G
Johansson, B
Nilsson, B
Mellstedt, H
Osterborg, A
机构
[1] KAROLINSKA HOSP,RADIUMHEMMET,DEPT ONCOL,S-17176 STOCKHOLM,SWEDEN
[2] KAROLINSKA HOSP,DEPT INTERNAL MED,S-17176 STOCKHOLM,SWEDEN
[3] KAROLINSKA HOSP,DEPT CANC EPIDEMIOL,S-17176 STOCKHOLM,SWEDEN
关键词
MGUS; monoclonal B lymphocytes; prognosis;
D O I
10.1046/j.1365-2141.1996.294826.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fifty-seven patients with monoclonal gammopathy of undetermined significance (MGUS) were analysed for the presence of blood clonal B-cell excess (CBE), defined as a lymphocyte surface membrane kappa/lambda light chain ratio outside the normal range (> 3.5 in kappa-type MGUS and <0.9 in lambda-type MGUS), 15 patients (26%) had a CBE. The patients were followed for a median time of 8.4 years (range 0.5-20.2). Eight of the 15 CBE(+) MGUS patients (53%) developed a B-cell malignancy as compared to 7/42 patients (17%) in the CBE group and the difference in event-free (malignancy-free) observation time was statistically significant (P=0.01). Cox's regression analysis showed that the presence of CBE was the most powerful predictor of progression to a malignant disease. Two patients with a normal kappa/lambda ratio at first test were analysed repeatedly during follow-up. Subsequently, a CBE appeared which gradually increased in size preceding the clinical diagnosis of a malignant disease.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 33 条
[1]  
AXELSSON U, 1966, ACTA MED SCAND, V179, P235
[2]   CIRCULATING MONOTYPIC B-CELLS IN MULTIPLE-MYELOMA - ASSOCIATION WITH LAMBDA PARAPROTEINS [J].
BAGG, A ;
BECKER, P ;
BEZWODA, W ;
VANRENSBURG, L ;
MENDELOW, B .
BRITISH JOURNAL OF HAEMATOLOGY, 1989, 72 (02) :167-172
[3]   EVIDENCE THAT THE CLONOGENIC CELL IN MULTIPLE-MYELOMA ORIGINATES FROM A PRE-SWITCHED BUT SOMATICALLY MUTATED B-CELL [J].
BAKKUS, MHC ;
VANRIET, I ;
VANCAMP, B ;
THIELEMANS, K .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (01) :68-74
[4]  
BAST EJEG, 1982, CLIN EXP IMMUNOL, V47, P677
[5]  
BERENSON J, 1987, BLOOD, V70, P1550
[6]  
BERGMANN L, 1985, SCAND J HAEMATOL, V34, P170
[7]   INTERLEUKIN-3 AND INTERLEUKIN-6 SYNERGISTICALLY PROMOTE THE PROLIFERATION AND DIFFERENTIATION OF MALIGNANT PLASMA-CELL PRECURSORS IN MULTIPLE-MYELOMA [J].
BERGUI, L ;
SCHENA, M ;
GAIDANO, G ;
RIVA, M ;
CALIGARISCAPPIO, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (02) :613-618
[8]  
BERLINER N, 1986, BLOOD, V67, P80
[9]  
BILLADEAU D, 1992, BLOOD, V80, P1818
[10]   THE BONE-MARROW OF MULTIPLE-MYELOMA PATIENTS CONTAINS B-CELL POPULATIONS AT DIFFERENT STAGES OF DIFFERENTIATION THAT ARE CLONALLY RELATED TO THE MALIGNANT PLASMA-CELL [J].
BILLADEAU, D ;
AHMANN, G ;
GREIPP, P ;
VANNESS, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1023-1031